X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PeptiCRAd-1 is an intratumoral injection vaccine, being investigated for Synovial Sarcoma treatment, in combination with Pembrolizumab and Cyclophosphamide.
Lead Product(s): PeptiCRAd-1,Pembrolizumab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: PeptiCRAd-1
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
The collaboration aims to investigate immune responses to PeptiCRAd-1 in its Phase 1 clinical study. PeptiCRAd-1 is the company’s lead product made up of its virus VALO-D102 coated with MAGE-A3 and NY-ESO-1 peptides.
Lead Product(s): PeptiCRAd-1,Pembrolizumab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: PeptiCRAd-1
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Texcell
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 13, 2023
Details:
PeptiCRAd-1 is a cancer immunotherapy drug candidate designed to stimulate systemic tumor-directed cytotoxic T-cell responses in cancer patients. Combined with its local immune modulation effect at the tumor site, it has the potential to deliver synergistic clinical outcomes.
Lead Product(s): VALO-D102,Cyclophosphamide,Pembrolizumab
Therapeutic Area: Oncology Product Name: PeptiCRAd-1
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
PeptiCRAd-1 is a cancer immunotherapy drug candidate designed to stimulate systemic tumor-directed cytotoxic T-cell responses in cancer patients. Combined with its local immune modulation effect at the tumor site, it has the potential to deliver synergistic clinical outcomes.
Lead Product(s): PeptiCRAd-1,Pembrolizumab
Therapeutic Area: Oncology Product Name: PeptiCRAd-1
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2023
Details:
VALO-D102 is a fundamental component of the company’s proprietary PeptiCRAd (peptide-coated Conditionally Replicating Adenovirus) immuno-oncology platform. PeptiCRAd combines two cancer immunotherapy approaches: an oncolytic Adenovirus and a peptide vaccine.
Lead Product(s): VALO-D102
Therapeutic Area: Oncology Product Name: VALO-D102
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Exothera
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 11, 2023
Details:
PeptiCHIP enables to identify antigens faster than existing technologies and, in combination with lead delivery platform, PeptiCRAd (unique way of combining two clinically proven cancer immunotherapy approaches: an oncolytic Adenovirus and a peptide vaccine).
Lead Product(s): PeptiCRAd
Therapeutic Area: Oncology Product Name: PeptiCRAd
Highest Development Status: DiscoveryProduct Type: Vaccine
Recipient: University of Helsinki
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 26, 2022
Details:
In immunological tumour animal models, pre-immunisation with tetanus specific peptides significantly enhanced responses following subsequent vaccination with tumour-peptide coated oncolytic Adenoviruses; ValoTx’s PeptiCRAd technology, in combination with anti-PD1.
Lead Product(s): PeptiCRAd-1
Therapeutic Area: Oncology Product Name: PeptiCRAd-1
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: University of Helsinki
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 06, 2022
Details:
Valo Tx, will use its proprietary PeptiVAX technology to coat a spike-expressing adenoviral vector vaccine with HLA-restricted peptides. These peptides may be associated with a clinically beneficial T cell immune responses to Sars-CoV-2's highly conserved genes.
Lead Product(s): Peptide based-pan Coronavirus vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Recipient: ImmunoScape
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 09, 2021
Details:
Valo Tx's PeptiCRAd technology to coat non-replicating adenovirus expressing COVID-19 Spike, with HLA-matched peptides tailored to boost immune responses of CD8 + T-cells.
Lead Product(s): COVID-19-adenovirus vector-based vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
Details:
With this collaboration, the parties will test whether PeptiCRAd coating of ONCOS-102 adenovirus with TG mutant RAS peptides can generate enhanced CD4+ and CD8+ T-cell responses against mutant RAS.
Lead Product(s): Antigen peptides,ONCOS-102 adenovirus
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Peptide
Partner/Sponsor/Collaborator: Targovax
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
